PROTEIN SAFETY OF PRESENT AND FUTURE GM PLANTS

Applicants meeting April 2024



PROTEIN SAFETY – RISK ASSESSMENT REQUIREMENTS AT PRESENT

Protein safety = protein toxicity and allergenicity

Codex 2003/2009 defined the principles for the assessment

- Main information considered:
 - 1. Knowledge on the source/protein HoSU
 - 2. Bioinformatics analysis
 - 3. In vitro studies


_

4. In vivo studies





FUTURE ADDITIONAL NEEDS – FROM EXPERIENCE GAINED



Need for complementary/alternative methods



3

DEVELOPMENT NEEDS

History of safety use	Toxicological assessment	Tiered approach using <i>in vivo</i> studies o concerns identified
Protein characterisation		
Mode of action		
Stability	Allergenicity assessment	Ranking of allergens[2] and post-marke monitoring
Source organism		
Phylogeny	,	
Structural/Functional similarity to known proteins		
Similarity to known toxins/allergens	n silic protei	ວ tools: information on the derived structure of th າ
Fate in the gastrointestinal tract	Appro odolo Ms) [
Interaction between proteins	In silico tools: information on the derived structure of the protein In vitro testing: stability tests could better inform about of the novel proteins during processing, storage and aft digestion in the gastrointestinal tract	
	Z Z digest	ion in the gastrointestinal tract

[2] EFSA GMO Panel, 2022. Scientific Opinion on development needs for the allergenicity and protein safety assessment of food and feed products derived from biotechnology. EFSA Journal 2022;20(1):7044

[3] Cattaneo et al., 2023. Implementing New Approach Methodologies (NAMs) in food safety assessments: Strategic objectives and actions taken by the European Food Safety Authority. Trends in Food Science & Technology, 133:277-290


EFSA GMO PANEL MANDATE

Scientific Opinion reflecting on <u>current practice</u>, <u>challenges</u> and <u>future opportunities</u> of protein safety in GMOs

- 1. Lessons learned from experiences in the assessment of newly expressed proteins in the last 20 years, including more recent complex cases
- Building on the experience and issues identified, develop a critical appraisal of new methodologies available with the potential to be used as complementary/ alternative testing strategies to current methodologies described in legal frameworks
- 3. Road map for future implementation of such complementary/alternative methods in risk assessment strategies
- 4. Recommendations for further research to address methodological development needs




WATERS ET AL 2021





WATERS ET AL 2021 AS WELL AS BRUNE ET AL 2021






ROPER ET AL 2021

- A stepwise approach is recommended to evaluate the safety of NEPs taking the totality of information into account
- Core studies
 - HoSU of the NEP demonstration of prior human/animal consumption or <u>closely related</u> proteins
 - No need for any specific toxicity or allergenicity testing in cases where both the plant and proteins expressed in the GM plant have a history of safe consumption by humans and animals – reference to EFSA guidance 2011
 - HoSU structural and/or functional similarity and exposure to other endogenous proteins
 - <u>The appropriate methods for establishing this similarity need to be determined on a caseby-case basis</u>
 - Bioinformatics results should be regarded as guiding rather than predictive
 - Intestinal epithelial cell line monolayers from rodents and humans have been investigated to evaluate the effects of known hazardous proteins, including ricin and PHA-E




HABIG ET AL 2018





STEPWISE APPROACH IN THE PROTEIN SAFETY ASSESSMENT

- Protein vs simple chemical safety assessments
- Comparative approach as baseline–HoSU, familiarity, knowledge on proteins
- What is considered safe?
- What is considered a hazard in protein safety?
- Structural/functional similarity; but how similar is similar?
- How can evidence of consumption of a protein or source be established?
- Is there a need or possible to have additional thresholds/cut-off values (e.g. bioinformatics)?
- Is in vitro testing ready to be used when needed?
- How can exposure be considered in protein safety WoE?



PROTEIN SAFETY ASSESSMENTS

Thank you very much!!!!



11

STAY CONNECTED



BRUNE ET AL 2021

- Protein safety CORE STUDIES
 - Toxicological assessment: As a result of the acidic conditions and digestive enzymes of the gastrointestinal tract, dietary proteins are typically rapidly degraded into small peptides and individual amino acids before absorption and metabolic use by the body
 - HoSU of the NEP
 - HoSU of the source organism
 - Bioinformatics for sequence comparison
 - Mode of action and functional specificity: If the mode of action and functional specificity of the NEP are well understood and have been shown to have low relevance to humans or animals, this provides confidence that it is unlikely to cause harm when consumed
 - Allergenicity
 - A stepwise approach is recommended where hazard identification is first performed for all NEPs. If a hazard is identified, exposure characterization should be done (supplementary info)
 - HoSU of the NEP and familiarity with the source organism
 - Aminoacid sequence similarity and bioinformatics: sequence level, structural relatedness, structural considerations



BRUNE ET AL 2021

Protein safety – SUPPLEMENTARY STUDIES

- Protein abundance in food and feed
- Processing
- Resistance to digestion
- Tox studies with animals
- Compositional analysis
- Dietary exposure assessment
- Case-by-case studies
 - Post translational modifications if identified, further studies needed as it can change physicochemical charac.
 - Mode of action
 - Substrate specificity

